| Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc |
| Journal website http://www.journalmc.org |
Case Report
Volume 10, Number 8, August 2019, pages 229-233
A Case of Intestinal Microsporidiosis in a Renal Transplant Recipient
Figures


Tables
| CMV: cytomegalovirus. |
| Drug related |
| Mycophenolate, tacrolimus, antibiotics, proton pump inhibitors, metformin |
| Infective causes |
| Bacterial: salmonella, C. difficile, campylobacter, shigella, yersinia |
| Viral: CMV, norovirus and rotavirus |
| Parasitic: cryptosporidium, giardia, entamoeba, microsporidia |
| Surgical causes |
| Intra-abdominal sepsis, mesenteric ischemia and colorectal carcinoma |
| Miscellaneous |
| Coeliac disease, irritable bowel syndrome, malabsorption syndrome, post-transplant lymphoproliferative disorder |
| CMV: cytomegalovirus. |
| Non-invasive |
| Stool: PCR, microscopy |
| Blood (serum): blood culture, CMV PCR and quantitative assay, immunosuppressive drug serum assays, immunological test for endomysial antibodies and transglutamase antibodies |
| Invasive |
| Biopsy: colonic, terminal ileum, gastric, duodenal |
| Article/reference | Intestinal/disseminated infection | Treatment agent/dose/duration | Outcome |
|---|---|---|---|
| Dacha et al [34] | Intestinal E. intestinalis | Albendazole 400 mg BD for 4 weeks | Effective |
| Galvan et al [14], patient 1 | Intestinal | Initially metronidazole, on relapse switched to albendazole 400 mg BD for 3 weeks | Albendazole effective |
| Galvan et al [14], patient 2 | Intestinal | Immunosuppression withdrawal | |
| George et al [8] | Disseminated | Albendazole 400 mg BD, duration not defined | Effective |
| Hocevar et al [26], patient 1 | Disseminated, E. cuniculi | Albendazole 400 mg BD for 4 months | Effective |
| Hocevar et al, 2014 [26], patient 2 | Disseminated due to E. cuniculi | Albendazole 400 mg BD for 1 year due to relapse | Effective |